AHR at a glance
American Healthcare REIT, Inc. (AHR, SEC CIK 1632970) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 6, 2026 and Form 4 insider filings as recently as November 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), American Healthcare REIT, Inc. (AHR) reported revenue of $2.1 billion (up 11.2% from FY2024) and net income of $69.8 million. Diluted EPS was $0.42.
- As of September 30, 2026, 35 institutional investment managers tracked by SignalX reported holding American Healthcare REIT, Inc. (AHR) shares worth $6.5 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Foster Mark E. on November 16, 2026 of 2,000 shares at $57.99 per share.
- In the last 90 days, AHR insiders reported 0 open-market purchases ($0) and 4 open-market sales ($453K) on Form 4, a net sale of $453K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $2.1B
- +11.2% vs prior year
- Insiders · 90 days
- 0 buys · 4 sells
- Net −$453K
- 13F holders
- 35 funds
- $6.5B · −4 vs prior quarter
- Latest 8-K
- Nov 6, 2026
- Item 1.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Self-managed REIT owning and operating clinical healthcare real estate including senior housing, skilled nursing, outpatient medical, across US, UK, Isle of Man
- New emphasis: Public offering in Feb 2024 raised $772.8M gross; NYSE listing under symbol "AHR" and consolidation of multiple common stock classes into one
- Strategic shift: Greater focus on integrated senior health campuses (ISHC) and senior-housing operating properties (SHOP) utilizing the RIDEA structure for enhanced operational and tax efficiency
- Quantitative highlight: Employee count approximately 121 as of December 31, 2025, with a significant capital raise via equity offering in 2024
- Noteworthy fact: Stock conversion on August 5, 2024, automatically combined Class T and Class I shares into listed common stock, streamlining capital structure post-IPO
Risk Factors
- Healthcare regulation risk: potential loss of tenants’ Medicare/Medicaid participation impacting rent payments under U.S. federal/state healthcare laws
- Macroeconomic threat: portfolio concentrated in healthcare real estate with 45.3% managed by Trilogy Manager contributing 55.5% of NOI as of 12/31/2025
- Operational vulnerability: reliance on Trilogy Manager for ISHC operations, risk from its financial, legal, or personnel difficulties could materially harm the company
- Competitive risk: significant competition for senior housing and healthcare facility acquisitions, with competitors possibly having greater resources and lower capital costs
- Financial risk: CEO Danny Prosky on medical leave timing unknown, interim CEO appointed, key-person dependency could materially affect management stability
Management Discussion & Analysis
- Revenue $2,260M, up 9.1% YoY from $2,070.7M, driven by ISHC resident fees increase of $144.1M and SHOP increase of $66.6M
- ISHC margin impacted by inflation and acquisition growth; real estate revenue decreased $21.3M, reflecting less OM and triple-net lease revenue
- Best segment ISHC with $1,763.9M resident fees; worst performing OM segment revenue declined from $134.7M to $126.1M
- Raised $379.8M via 2024 ATM, $701.4M via 2025 ATM, and $447.1M in November 2025 offering; acquired $1.05B in properties and disposed $60.4M assets
- Management cautious on inflation, labor costs, potential interest rate rise; expects rent and care fee increases to offset cost pressures
AI summary of the AHR 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $742.149M, up $169.212M YoY from $572.937M
- Property operating margin 19.4% vs 14.6% YoY, with SHOP strongest at 27.7% vs 20.1%
- SHOP best growth: revenue $166.904M, up $90.298M YoY
- Cash $258.672M vs $184.363M, operating cash flow $366.579M, equity proceeds drove $1.966B financing cash inflow
- Inflation 3.7%, labor and supply costs remained near-term profitability headwinds
Risk Factors
- No material changes from risk factors disclosed in the 2025 Form 10-K
AI summary of the AHR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.01: Entry into a Material Definitive Agreement
- New ATM program authorizes up to $1.75 billion of common-stock sales, creating substantial potential equity funding and dilution
- Prior ATM terminated with approximately $170.134 million unsold, replacing rather than adding to the previous authorization
Item 2.02: Results of Operations and Financial Condition
- Earnings release covers financial position as of September 30, 2026
- Quarterly results announced for the quarter ended September 30, 2026
Item 7.01: Regulation FD Disclosure
- Supplemental data and investor presentation released for quarter ended September 30, 2026
- Exhibit 99.2 provides detailed quarterly operating and financial information
Item EX-99.1: Item EX-99.1
- Q3 NFFO $0.58 per diluted share, up from $0.44, supporting stronger recurring earnings
- Same-Store NOI growth 13.8%, led by SHOP at 28.2% and ISHC at 15.7%
Item EX-99.2: Item EX-99.2
- Q3 2026 supplemental reports strong operating momentum, with same-store NOI up 13.8% and NFFO per share up 31.8% to $0.58
- ISHC same-store NOI increased 15.7%, supported by occupancy rising 111 bps to 91.2% and margin expanding to 21.0%
Item 8.01: Other Events
- Quarterly cash distribution of $0.25 per common share for Q3 2026
- Annualized distribution rate of $1.00 per share
Item EX-99.1: Item EX-99.1
- Quarterly distribution declared at $0.25 per share for Q3 2026
- Record date September 30, 2026; cash payment scheduled on or about October 16, 2026
Item 7.01: Regulation FD Disclosure
- Press release announces American Healthcare REIT’s third quarter 2026 distribution
- Distribution details in Exhibit 99.1, relevant to income-oriented shareholders
AI summaries of AHR 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for AHR
Don't miss the next AHR filing
- Alerts as it files. A push when AHR files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut AHR, by share count.
- Ask anything. An AI agent that reads every AHR filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Foster Mark E. | Sell | Nov 16, 2026 | 2,000 | $57.99 |
| ESTES SCOTT A | Sell | Nov 10, 2026 | 2,500 | $59.32 |
| Foster Mark E. | Sell | Sep 25, 2026 | 1,500 | $52.06 |
| Foster Mark E. | Sell | Sep 1, 2026 | 2,000 | $55.39 |
| Prosky Danny | M | Jul 21, 2026 | 30,886 | - |
| Hanson Jeffrey T | A | Jul 21, 2026 | 35,981 | - |
| Prosky Danny | A | Jul 21, 2026 | 2,594 | - |
| Prosky Danny | M | Jul 21, 2026 | 30,886 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $1.7B | $1.9B | $2.1B |
| Operating Income | $306.8M | $363.5M | $415.2M |
| Net Income | -$71.5M | -$37.8M | $69.8M |
| Op. Margin | 18.4% | 19.3% | 19.8% |
| Net Margin | -4.3% | -2.0% | 3.3% |
| Balance Sheet | |||
| Total Assets | - | $4.5B | $5.4B |
| Equity | $1.3B | $2.3B | $3.3B |
| ROE | -5.6% | -1.7% | 2.1% |
| Per Share | |||
| EPS | $-1.08 | $-0.29 | $0.42 |
| Cash Flow | |||
| Operating CF | $98.5M | $176.1M | $294.4M |
Source: XBRL data in American Healthcare REIT, Inc. (AHR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate AHR share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 35 | $6.48B |
| Q2 2026 | 39 | $5.86B |
| Q1 2026 | 36 | $4.95B |
| Q4 2025 | 33 | $4.16B |
| Q3 2025 | 30 | $3.50B |
| Q2 2025 | 31 | $2.91B |
| Q1 2025 | 30 | $1.66B |
| Q4 2024 | 25 | $1.28B |
- BlackRock+6.80M (+26%)
- COHEN & STEERS, INC.+3.01M (+71%)
- Morgan Stanley+2.63M (+110%)
- Millennium Management+1.16M (+58%)
- D.E. Shaw & Co+1.07M (+2350%)
- Goldman Sachs Group−458.2K (-45%)
- Two Sigma Investments−261.5K (-17%)
- Bank of America Corp−236.9K (-5%)
- AQR Capital Management−70.1K (-44%)
- Citadel Advisors LLC−14.9K (-1%)
- FMR LLC (Fidelity)−4.57M
- Soros Fund Management−428.6K
- Blackstone Group−39.5K
- Equitable Holdings Inc−6.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 259 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
AHR filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 10, 2026 | - | - | - |
| 8-K | Nov 6, 2026 | - | Analysis | - |
| 10-Q | Nov 6, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 4 | Sep 28, 2026 | - | - | - |
| 8-K | Sep 18, 2026 | - | Analysis | - |
| 8-K | Sep 14, 2026 | - | Analysis | - |
| 8-K | Sep 2, 2026 | - | Analysis | - |
| 8-K | Sep 1, 2026 | - | Analysis | - |
| 4 | Sep 1, 2026 | - | - | - |
| 8-K | Aug 24, 2026 | - | Analysis | - |
| 8-K | Aug 12, 2026 | - | Analysis | - |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| SC 13G | Aug 7, 2026 | - | - | |
| 10-Q | Aug 7, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Jul 22, 2026 | - | - | - |
| 4 | Jul 22, 2026 | - | - | - |
| 8-K | Jul 22, 2026 | - | Analysis | - |
| 4 | Jul 22, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
Related Real Estate companies
- AKR · ACADIA REALTY TRUSTReal Estate Investment Trusts
- ACR · ACRES Commercial Realty Corp.Real Estate Investment Trusts
- ADAM · ADAMAS TRUST, INC.Real Estate Investment Trusts
- ALX · ALEXANDERS INCReal Estate Investment Trusts
- ARE · Alexandria Real Estate EquitiesReal Estate Investment Trusts
- PINE · Alpine Income Property Trust, Inc.Real Estate Investment Trusts
- AAT · American Assets Trust, Inc.Real Estate Investment Trusts
- AMT · American TowerReal Estate Investment Trusts
AHR SEC filings: frequently asked questions
Are AHR insiders buying or selling?
In the last 90 days, American Healthcare REIT, Inc. (AHR) officers, directors and 10% owners reported no open-market purchases and 4 open-market sales worth $453,150 by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold AHR stock?
As of September 30, 2026, the largest American Healthcare REIT, Inc. (AHR) holders among the 13F filers tracked by SignalX were BlackRock ($1.7 billion), Vanguard Portfolio Management LLC ($907.8 million), Vanguard Capital Management LLC ($522.5 million), State Street Corp ($509.2 million), Principal Financial Group ($459.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was AHR's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), American Healthcare REIT, Inc. (AHR) reported revenue of $2.1 billion (up 11.2% from FY2024) and net income of $69.8 million. Diluted EPS was $0.42. The figures come from the XBRL data in the 10-K.
What are the main risks in AHR's latest 10-K?
In the 10-K filed February 27, 2026, American Healthcare REIT, Inc. (AHR) flagged: Healthcare regulation risk: potential loss of tenants’ Medicare/Medicaid participation impacting rent payments under U.S. federal/state healthcare laws. Macroeconomic threat: portfolio concentrated in healthcare real estate with 45.3% managed by Trilogy Manager contributing 55.5% of NOI as of 12/31/2025. (AI summary of the Risk Factors section.)
What did AHR report in its latest 8-K?
American Healthcare REIT, Inc. (AHR) filed an 8-K on November 6, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). New ATM program authorizes up to $1.75 billion of common-stock sales, creating substantial potential equity funding and dilution.
What are the latest AHR SEC filings?
American Healthcare REIT, Inc. (AHR) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 6, 2026 and a Form 4 insider filing on November 17, 2026.
What is AHR's SEC CIK number?
American Healthcare REIT, Inc. (AHR)'s SEC Central Index Key (CIK) is 1632970. EDGAR lists every AHR filing under that number.
Ask anything about AHR
The research agent reads AHR's filings, financials, insider trades and 13F holders, then answers with sources.